"Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and up to $25 billion projected for 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth was one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product. Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side effect."
"Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the United States in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone."
"Besides Ozempic and Wegovy, the company has made progress recently on other obesity drugs in its pipeline, including amycretin and CagriSema. Novo Nordisk has reported promising clinical trial results for a new weight-loss pill, a major corporate restructuring, and continued success for its blockbuster drugs."
Ozempic generated about $17 billion in sales in 2024, with projections up to $25 billion for 2025, driving substantial revenue growth for Novo Nordisk. Novo Nordisk's market value exceeded $500 billion, surpassing Denmark's GDP. The company began making insulin a century ago and became Novo Nordisk in 1989 after U.S. expansion and corporate changes. The product portfolio includes diabetes drugs, wound-healing treatments, menopausal hormone replacement, and human growth hormone. The pipeline includes amycretin (FDA phase 1) and CagriSema (phase 2), along with promising clinical results for a new weight-loss pill and a major corporate restructuring. Investors remain concerned about long-term stock performance amid market projections and uncertainties.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]